알츠하이머, 파킨슨병 치료제 및 조기진단법 개발
Location: Spain, Community of Madrid, Madrid
Employees: 51-200
Total raised: $45M
Founded date: 2016
Investors 2
| Date | Name | Website |
| 04.06.2022 | Quantum Ve... | quantumepk... |
| - | SBI Invest... | sbik.co.kr |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.02.2022 | Series C | $45M | - |
Mentions in press and media 12
| Date | Title | Description |
| 17.07.2023 | BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program | Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS Underpinned by proprietary IV-formulated, Brain-targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiNTM) platform BIORCHESTRA to receive in-kind product... |
| 01.06.2023 | BIORCHESTRA Invited to Present Update on Central Nervous System Lead Program (BMD-001) and IV-Formulated siRNA Data at BIO2023 International Conference | Presentation:"Successfully Achieving Intravenous (IV)-formulated RNA Delivery to the Brain, Evidence of Efficacy" scheduled for June 08, 2023, 12:00 p.m. ET, Room 104A Pioneering IV-formulated inert drug delivery platform targetin... |
| 25.04.2023 | BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States | The Official State visit by the President of the Republic of Korea marks the 70th anniversary of the U.S.-ROK alliance, which is advancing peace, stability, and prosperity for the two countries, for the Asia-Pacific region, and globally Pre... |
| 24.04.2023 | BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program | Encouraging non-human primate (NHP) findings support the progression of IV-formulated BMD-001 ahead of formal clinical studies for Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease Further validation of Brain Targe... |
| 05.04.2023 | BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer | CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) leveraging the Biorchestra Dr... |
| 27.03.2023 | BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies | Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform - BDDS™ - to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets CAMB... |
| 08.03.2023 | BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events | CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging its proprietary... |
| 15.12.2022 | BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy | A leader in creating jobs through the advancement of RNA-based therapeutics A contributor to a high employment rate in Korea's healthcare industry BOSTON, Dec. 15, 2022 /PRNewswire/ -- BIORCHESTRA ("BIORCHESTRA" or the "Compa... |
| 09.06.2022 | BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention | BOSTON, June 9, 2022 /PRNewswire/ -- BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a company presentation on June 16, 12:00 at BIO International convention, taking place in San Diego, California, between June 13-16, 2022. BIORCEH... |
| 28.02.2022 | Biorchestra Raises $45M in Series C Funding | Biorchestra, a Daejeon, South Korea, and Cambridge, Massachusetts, USA-based RNA therapeutics company, raised $45M in Series C funding. Participants in the Series C included Daily Partners, IMM Investment, SBI Investment, LSK Investment, E&... |
Show more